Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of COVID-19 on Psoriasis Practice

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04581044
Recruitment Status : Completed
First Posted : October 9, 2020
Last Update Posted : November 13, 2020
Sponsor:
Information provided by (Responsible Party):
Mona El-Kalioby, Cairo University

Tracking Information
First Submitted Date October 6, 2020
First Posted Date October 9, 2020
Last Update Posted Date November 13, 2020
Actual Study Start Date September 17, 2020
Actual Primary Completion Date October 23, 2020   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: November 10, 2020)
  • Questionnaire to assess 1) Prescription pattern for Psoriasis patients during COVID-19 2) Management pattern for Psoriasis patients during COVID-19 [ Time Frame: 2-4 weeks ]
  • Questionnaire to assess 1) Impact of COVID-19 on the course of psoriasis in patients 2) Impact of COVID-19 on the psoriasis patients behaviour [ Time Frame: 2-4 ]
Original Primary Outcome Measures
 (submitted: October 7, 2020)
  • Questionnaire to assess 1) Change in prescription pattern for Psoriasis patients during COVID-19 2) Change in management pattern for Psoriasis patients during COVID-19 [ Time Frame: 2-4 weeks ]
  • Questionnaire to assess 1) Impact of COVID-19 on the course of psoriasis in patients 2) Impact of COVID-19 on the psoriasis patients behaviour [ Time Frame: 2-4 ]
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Impact of COVID-19 on Psoriasis Practice
Official Title Impact of COVID-19 on Psoriasis Practice: A Cross Sectional Study
Brief Summary

COVID-19 had a major impact on dermatology practice globally with special emphasis on chronic diseases e.g. psoriasis. The main objective of this work is to investigate the effect of COVID-19 pandemic on psoriasis management.

This work is designed as a cross-sectional survey based on a questionnaire directed to Egyptian dermatologists.

Detailed Description Not Provided
Study Type Observational
Study Design Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Target Follow-Up Duration Not Provided
Biospecimen Not Provided
Sampling Method Non-Probability Sample
Study Population Egyptian Dermatologists
Condition
  • Psoriasis
  • Covid19
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Completed
Actual Enrollment
 (submitted: November 10, 2020)
197
Original Estimated Enrollment
 (submitted: October 7, 2020)
150
Actual Study Completion Date October 23, 2020
Actual Primary Completion Date October 23, 2020   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Egyptian Dermatologists
Sex/Gender
Sexes Eligible for Study: All
Ages 25 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers Yes
Contacts Contact information is only displayed when the study is recruiting subjects
Listed Location Countries Egypt
Removed Location Countries  
 
Administrative Information
NCT Number NCT04581044
Other Study ID Numbers KAPU2020 10
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement Not Provided
Responsible Party Mona El-Kalioby, Cairo University
Study Sponsor Cairo University
Collaborators Not Provided
Investigators Not Provided
PRS Account Cairo University
Verification Date November 2020